Detalhe da pesquisa
1.
Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis: A Clinical Trial.
Am J Respir Crit Care Med
; 205(5): 529-539, 2022 03 01.
Artigo
Inglês
| MEDLINE | ID: mdl-34784492
2.
Comparative Effectiveness of Vancomycin Versus Linezolid for the Treatment of Acute Pulmonary Exacerbations of Cystic Fibrosis.
Ann Pharmacother
; 54(3): 197-204, 2020 03.
Artigo
Inglês
| MEDLINE | ID: mdl-31658825
3.
Elexacaftor/tezacaftor/ivacaftor and gastrointestinal outcomes in cystic fibrosis: Report of promise-GI.
J Cyst Fibros
; 22(2): 282-289, 2023 03.
Artigo
Inglês
| MEDLINE | ID: mdl-36280527
4.
PROMISE: Working with the CF community to understand emerging clinical and research needs for those treated with highly effective CFTR modulator therapy.
J Cyst Fibros
; 20(2): 205-212, 2021 03.
Artigo
Inglês
| MEDLINE | ID: mdl-33619012
5.
Vancomycin Versus Vancomycin Plus Rifampin for the Treatment of Acute Pulmonary Exacerbations of Cystic Fibrosis.
J Pediatr Pharmacol Ther
; 23(2): 125-131, 2018.
Artigo
Inglês
| MEDLINE | ID: mdl-29720914
6.
Association of Vancomycin Trough Concentration With Response to Treatment for Acute Pulmonary Exacerbation of Cystic Fibrosis.
J Pediatric Infect Dis Soc
; 6(3): e103-e108, 2017 Sep 01.
Artigo
Inglês
| MEDLINE | ID: mdl-28903517
7.
Clinical and molecular characterization of S1118F-CFTR.
Pediatr Pulmonol
; 44(10): 1003-9, 2009 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-19774621